Literature DB >> 13468837

Psychomotility and parkinsonism in treatment with neuroleptic drugs.

F A FREYHAN.   

Abstract

Entities:  

Keywords:  CHLORPROMAZINE/therapeutic use; MENTAL DISORDERS/therapy; MOVEMENT; PARALYSIS AGITANS/etiology and pathogenesis; RESERPINE/therapeutic use

Mesh：

Substances：

Year:  1957        PMID： 13468837     DOI： 10.1001/archneurpsyc.1957.02330410029003

Source DB:  PubMed          Journal:  AMA Arch Neurol Psychiatry        ISSN： 0096-6886


× No keyword cloud information.
  6 in total

1.  TREATMENT OF DRUG-INDUCED PARKINSONISM: A COMPARISON BETWEEN UK-738, ORPHENADRINE, AND A PLACEBO IN A DOUBLE BLIND STUDY.

Authors:  K JENSEN; A AMDISEN
Journal:  Psychopharmacologia       Date:  1964-03-11

2.  Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.

Authors:  R J Hardie; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 3.  Drug-induced parkinsonism in the elderly: incidence, management and prevention.

Authors:  José Luis López-Sendón; María Angeles Mena; Justo García de Yébenes
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

Review 4.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

5.  Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.

Authors:  L Farde
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  A study of prophylactic value of antiparkinsonian drug.

Authors:  P B Behere; P Ramakrishna
Journal:  Indian J Psychiatry       Date:  1983-07       Impact factor: 1.759
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.